Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13625659 | 0.81 | RAB9A (0.50) | DAORAB9ASMN1; SMN2PKMGAA | |
| SCHEMBL1149500 | 0.81 | DAO (0.43) | DAOTDP1 | |
| SCHEMBL27712207 | 0.77 | MCL1 (0.41) | DAORAB9AMCL1GPR84SLC18A3 | |
| SCHEMBL7258022 | 0.74 | DAO (0.57) | DAORAB9ASMN1; SMN2PKMGAA | |
| SCHEMBL28760413 | 0.73 | RAB9A (0.56) | RAB9ASMN1; SMN2PKMGAAMEN1 | |
| SCHEMBL1149736 | 0.73 | DAO (0.64) | DAORAB9ASMN1; SMN2GAATDP1 | |
| SCHEMBL5858576 | 0.73 | DAO (0.55) | DAOGPR84MEN1KMT2A | |
| SCHEMBL8390700 | 0.72 | DAO (0.54) | DAOGPR84MEN1KMT2A | |
| SCHEMBL9050786 | 0.72 | DAO (0.54) | DAOGPR84MEN1KMT2A | |
| SCHEMBL1225699 | 0.71 | DAO (0.60) | DAORAB9ASMN1; SMN2PKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092559-A1 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092559-A1 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7893098-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893098-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-7615572-B2 | 4,5-substituted pyrazole-3-carboxylic acids/esters/salts; D-amino acid oxidase (DAAO) inhibitors; increase D-Serine level; reduce level of toxic products of D-Serine oxidation; activate N-methyl-D-aspartate NMDA-glutamate receptors; neuropathic agent, schizophrenia, Alzheimer's, anaxia | SEPRACOR INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7488747-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20050143443-A1 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092559-A1 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | DDO, DAO, SRR | DAO 2/4885RAB9A 2111/4885SMN1; SMN2 640/4885 |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | DDO, DAO, SRR | DAO 2/4885RAB9A 2111/4885SMN1; SMN2 640/4885 |
| US-20050143443-A1 | Pyrrole and pyrazole DAAO inhibitors | DDO, DAO, SRR | DAO 2/4885RAB9A 2111/4885SMN1; SMN2 640/4885 |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | DDO, DAO, SRR | DAO 2/4885RAB9A 2111/4885SMN1; SMN2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.